Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Vanda Pharmaceuticals Inc.
VNDA · Price history
Price at last available close
$3.84
−$1.07 (-21.79%) 1M
2026-10-30
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Vanda Pharmaceuticals Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds.
How they make money
Vanda Pharmaceuticals is a biopharmaceutical company that generates revenue primarily through the commercialization and sale of its proprietary pharmaceutical products, Fanapt and HETLIOZ. The company relies on a direct sales force to market these therapies to healthcare providers in the United States and utilizes distribution agreements to reach international markets.
Products & services
Vanda's commercial portfolio includes Fanapt (iloperidone) for schizophrenia and bipolar I disorder, and HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorder.
Brands & revenue mix
Oral tablets for the treatment of schizophrenia and bipolar I disorder.
Separate brand revenue is not available in this research.Source
Therapy for non-24-hour sleep-wake disorder.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's revenue is concentrated among a limited number of wholesale pharmaceutical distributors, which is typical for the industry as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its drug products and active pharmaceutical ingredients.Source
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Total debt increased 96.2% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
29
Poor
Financial Strength
36
Business Quality / Moat
18
Management
40
Growth Quality
18
Risk / Durability
30
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
31
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for VNDA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving VNDA's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can VNDA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is VNDA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for VNDA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify VNDA's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
31
Market Cap
$232.2M
P/E Ratio
-0.8
EPS
$-4.63
52-Week High
$9.94
52-Week Low
$3.79
Beta
0.69
Analyst Target
$15.50
Shares Outstanding
58.9M
Total Revenue
$215.7M
Total Debt
$22.8M
Dividend
No current dividend
Liquidation Value / Share
$3.74
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on VNDA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary product portfolio with established market presence.
- +Expertise in pharmacogenetics and drug development.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on a limited number of commercial products.
- −Risks associated with clinical development and regulatory approval.
- −Intellectual property litigation and generic competition.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
26
Oct 26, 2026
Change
Unchanged
Current Score
26
Oct 28, 2026
Category Changes
VNDA score was unchanged.
Projected Score
Projected Score
26
Projected Change
+0.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.84
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $215.7M | $216.1M | $198.8M | $192.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $15.5M | $13.0M | $11.3M | $14.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $200.2M | $203.1M | $187.5M | $177.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $117.0M | $109.3M | $74.4M | $76.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $263.4M | $238.0M | $146.4M | $112.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $385.9M | $354.2M | $228.1M | $191.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$164.9M | -$126.7M | -$14.8M | $9.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$185.7M | -$151.2M | -$40.7M | -$14.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$177.2M | -$138.6M | -$22.9M | $6.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $97.7M | $81.8M | -$4.0M | $3.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$274.9M | -$220.5M | -$18.9M | $2.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.63 | $-3.74 | $-0.32 | $0.04 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 60.23M | 58.93M | 58.15M | 57.38M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 60.23M | 58.93M | 58.15M | 57.56M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$50.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.04
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+96.2%
Cash Change
-31.0%
Margin Change
-72.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 3.9%. EPS increased 126.1%. Cash declined 31.0%. Total debt increased 96.2%. Net income margin declined by 72.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Rumor Mill · VNDA
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial